Tegoprazan to treat gastroesophageal reflux disease

J. Mermelstein, A. C. Mermelstein, M. M. Chait

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Gastroesophageal reflux disease (GERD) is the most common upper gastrointestinal disorder in the United States. Although proton pump inhibitors (PPIs) are the mainstay of therapy for GERD and its complications, they have several limitations, including incomplete symptom resolution. Potassium-competitive acid blockers (P-CABs) were developed to address the limitations of PPIs as well as the need for improved antisecretory effects. Tegoprazan, the newest P-CAB, was approved in 2018 in South Korea for the treatment of erosive esophagitis (EE) and nonerosive reflux disease (NERD). A highly selective inhibitor of the H+/K+-ATPase, tegoprazan is also safe and effective for nocturnal acid breakthrough (NAB) and motility. Further studies of tegoprazan are warranted to define its potential role in the treatment of acid-related disorders.

Original languageEnglish
Pages (from-to)715-721
Number of pages7
JournalDrugs of Today
Issue number11
StatePublished - Nov 2020
Externally publishedYes


  • CJ-12420
  • Esophageal diseases
  • Gastric acid secretion
  • Gastroesophageal reflux disease (GERD)
  • Gastrointestinal disorders
  • Potassium-competitive acid blocker (P-CAB)
  • Tegoprazan


Dive into the research topics of 'Tegoprazan to treat gastroesophageal reflux disease'. Together they form a unique fingerprint.

Cite this